The Th-1 cancer phenotype is characterized by responsiveness to immunotherapy.
This phenotype is accompanied by activation of counter-regulatory mechanisms.
Tumor genetic program modulates the development of the Th-1 cancer phenotype.
Oncogenic pathways can be targeted to enhance the efficacy of cancer immunotherapy.